Slilaty Steve N.
Known title: Chief Executive OfficerCIK: 0001474684
Slilaty Steve N.'s purchase track record
Slilaty Steve N. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2024 | SBFM | $10K | -86.9% | -96.9% | +7.8% |
| 2/8/2024 | SBFM | $2K | -96.0% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SBFM | ▲ Buy | Open Market | 100,000 | $10K | 3/4/2024 | View on chart |
| SBFM | ▲ Buy | Open Market | 20,000 | $2K | 2/8/2024 | View on chart |
| SBFM | ▼ Sell | Other | 990,000 | $99K | 2/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Sunshine Biopharma Amends Charter for Reverse Split
Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.
Sunshine Biopharma Amends Charter for Reverse Split. Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.